砷酸、原砷酸 | 7778-39-4

• 分子结构分类: 无机化合物 - 混合金属/非金属化合物 - 各种混合金属/非金属
• 中文名称: 砷酸、原砷酸
• 中文别名: 砷酸(剧毒)
• 英文名称: Arsenic acid
• 英文别名: orthoarsenic acid；Hydron;arsorate
• CAS: 7778-39-4
• 化学式: AsH₃O₄
• 分子量: 141.943
• InChiKey: DJHGAFSJWGLOIV-UHFFFAOYSA-N

物化性质

• 熔点：
  35 °C
• 密度：
  2.2 g/cm3
• 物理描述：
  Solid
• 颜色/状态：
  WHITE TRANSLUCENT CRYSTALS /HEMIHYDRATE/
• 沸点：
  Boiling point (-H2O): 160 °C /Hemihydrate/
• 溶解度：
  Solubility in water at 20 °C: very good
• 蒸汽压力：
  Vapor pressure, kPa at 15 °C: 1.3
• 稳定性/保质期：

  在-30℃时，H7AsO6（即As2O5·7H2O）会析出结晶；而当加热至175℃时，则从溶液中析出 ·5/3H2O。无论是哪种水合物，在250～300℃的温度下都会脱水变为 。

  在100克水中溶解的 量如下：0℃时为37.3克，10℃时为38.3克，20℃时为39.7克，100℃时为43.3克。

• 分解：
  When heated to decomposition it emits toxic fumes of arsenic.
• 腐蚀性：
  IT WILL SLOWLY ATTACK MILD STEEL & REACTS WITH GALVANIZED METALS AND BRASS
• 解离常数：
  PK2= 7.089 +/- 0.01 @ 25 °C

计算性质

• 辛醇/水分配系数(LogP)：
  -2.17
• 重原子数：
  5
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  77.8
• 氢给体数：
  3
• 氢受体数：
  4

ADMET

代谢

对雄性和雌性仓鼠给予单次口服或静脉注射剂量的24小时尿液样本分析（每只仓鼠33微居里；每只仓鼠0.01微克，作为砒酸），结果显示砷以二甲砷酸形式和无机砷形式存在。

ANALYSIS OF SAMPLES OF 24 HR URINE FROM MALE & FEMALE HAMSTERS GIVEN EITHER A SINGLE ORAL OR IV DOSE (33 MICROCURIES/HAMSTER; 0.01 UG/HAMSTER) AS ARSENIC ACID, REVEALED THAT ARSENIC WAS PRESENT AS DIMETHYLARSINIC ACID & AS INORGANIC ARSENIC.

来源:Hazardous Substances Data Bank (HSDB)

代谢

静脉注射无载体(74)锑酸至成年雄性比格犬（14.8 MBq, 0.4 mL）后，导致(74)锑主要以无机锑或二甲锑酸的形式存在于血浆或尿液中。

The iv administration of carrier free (74)As arsenic acid to an adult male beagle (14.8 MBq, 0.4 m C1), resulted in (74)As being present in plasma or urine predominantly as inorganic arsenic or dimethylarsenic acid.

来源:Hazardous Substances Data Bank (HSDB)

代谢

血浆、红细胞或比格犬的尿液在体外与(74)砷酸共培养。在血浆或尿液样本中没有发现甲基化砷，但在红细胞样本中发现了少量(0.2%)的二甲砷酸。

Plasma, red blood cells, or urine from a beagle were incubated in vitro with (74)As arsenic acid. No methylated arsenic was found in the plasma or urine samples but a small amt (0.2 %) of dimethylarsenic acid was found in the erythrocyte samples.

来源:Hazardous Substances Data Bank (HSDB)

代谢

大鼠肝细胞质通过甲基化使无机砷失活；S-腺苷甲硫氨酸是甲基供体，还原型谷胱甘肽对完全活性是必需的。...途径涉及形成一种单甲基化代谢物，这种代谢物要么迅速进一步甲基化成二甲基衍生物，要么自发氧化成单甲基砷酸。二甲基化代谢物产生二甲基砷酸。第一次甲基化反应是限速步骤，可以被谷胱甘肽刺激，并且由不同于转移第二个甲基团的酶催化。后者对无机砷的抑制作用敏感。...大量的巯基可能会通过减少自由三价砷的量来阻止甲基化反应。

Rat liver cytosol inactivates inorganic arsenic through methylation; S-adenosylmethionine is the methyl group donor and reduced glutathione is required for full activity. ... Pathway involves the formation of a monomethylated metabolite which is either rapidly further methylated into a dimethylated derivative or is spontaneously oxidized into monomethylarsonic acid. The dimethylated metabolite gives rise to dimethylarsinic acid. The first methylation reaction is rate limiting, can be stimulated by glutathione and is catalyzed by an enzyme different from that which transfers the second methyl group. The latter is sensitive to inhibition by inorganic arsenic. ... A large excess of thiol groups may prevent the methylation reactions probably by decreasing the amount of free trivalent arsenic.

来源:Hazardous Substances Data Bank (HSDB)

代谢

砒霜主要通过吸入或摄入进入人体，其次是皮肤接触。进入人体后，砒霜会被还原成亚砷酸盐，然后通过亚砷酸盐甲基转移酶被甲基化成单甲基砷（MMA）和二甲基硅酸（DMA）。砒霜及其代谢物主要通过尿液排出体外。已知砒霜可以诱导金属结合蛋白金属硫蛋白，通过结合砒霜和其他金属并使其生物活性失效，以及作为抗氧化剂的作用，从而降低砒霜和其他金属的有毒效果。

Arsenic is mainly absorbed by inhalation or ingestion, and to a lesser extent by dermal exposure. It is then distributed throughout the body, where it is reduced into arsenite, then methylated into monomethylarsenic (MMA) and dimethylarsenic acid (DMA) by arsenite methyltransferase. Arsenic and its metabolites are primarily excreted in the urine. Arsenic is known to induce the metal-binding protein metallothionein, which decreases the toxic effects of arsenic and other metals by binding them and making them biologically inactive, as well as acting as an antioxidant. (L20)

来源:Toxin and Toxin Target Database (T3DB)

毒理性

• 毒性总结

砷及其代谢物通过多种机制干扰ATP的产生。在柠檬酸循环层面，砷抑制了丙酮酸脱氢酶。通过竞争磷酸盐，它解偶联了氧化磷酸化，从而抑制了与能量相关的NAD+的还原、线粒体呼吸和ATP合成。过氧化氢的产生也增加了，这可能形成活性氧物种和氧化应激。砷的致癌性受到砷与微管蛋白结合的影响，这导致非整倍体、多倍体和有丝分裂停滞。其他砷蛋白靶点的结合也可能导致DNA修复酶活性改变、DNA甲基化模式改变和细胞增殖。

Arsenic and its metabolites disrupt ATP production through several mechanisms. At the level of the citric acid cycle, arsenic inhibits pyruvate dehydrogenase. By competing with phosphate it uncouples oxidative phosphorylation, thus inhibiting energy-linked reduction of NAD+, mitochondrial respiration, and ATP synthesis. Hydrogen peroxide production is also increased, which might form reactive oxygen species and oxidative stress. Arsenic's carginogenicity is influenced by the arsenical binding of tubulin, which results in aneuploidy, polyploidy and mitotic arrests. The binding of other arsenic protein targets may also cause altered DNA repair enzyme activity, altered DNA methylation patterns and cell proliferation. (T1, A17)

来源:Toxin and Toxin Target Database (T3DB)

毒理性

• 致癌性证据

致癌性分类：1）人类证据：充分；2）动物证据：有限。对人类致癌风险评估的整体总结评价为第1组：对人类致癌。注意：此评估适用于整个化学物质组，而不一定适用于组内所有单个化学物质。/砷和砷化合物/

Classification of carcinogenicity: 1) evidence in humans: sufficient; 2) evidence in animals: limited. Overall summary evaluation of carcinogenic risk to humans is Group 1: Carcinogenic to humans. NOTE: This evaluation applies to the group of chemicals as a whole and not necessarily to all individual chemicals within the group. /Arsenic and arsenic compounds/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 致癌性证据

癌症分类：A组人类致癌物

Cancer Classification: Group A Human Carcinogen

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 致癌性证据

分类：A；人类致癌物。分类依据：基于足够的人类数据。在主要通过吸入暴露的多个人类群体中观察到了肺癌死亡率的增加。此外，在饮用富含无机砷的饮用水的群体中，观察到多种内部器官癌症（肝脏、肾脏、肺和膀胱）的死亡率增加以及皮肤癌发病率的增加。人类致癌性数据：充分。动物致癌性数据：不充分。/无机砷/ /基于先前的分类系统/

CLASSIFICATION: A; human carcinogen. BASIS FOR CLASSIFICATION: Based on sufficient evidence from human data. An increased lung cancer mortality was observed in multiple human populations exposed primarily through inhalation. Also, increased mortality from multiple internal organ cancers (liver, kidney, lung, and bladder) and an increased incidence of skin cancer were observed in populations consuming drinking water high in inorganic arsenic. HUMAN CARCINOGENICITY DATA: Sufficient. ANIMAL CARCINOGENICITY DATA: Inadequate. /Inorganic Arsenic/ /based on former classification system/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 致癌性证据

A1：已确认的人类致癌物。/砷和无机砷化合物，如As/

A1: Confirmed human carcinogen. /Arsenic and inorganic compounds, as As/

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

系统性的毒性效应是由于职业事故造成的，当时砒酸溅到了工人身上，这表明皮肤可能是砒吸收的可能途径。

SYSTEMIC TOXIC EFFECTS HAVE RESULTED FROM OCCUPATIONAL ACCIDENTS WHEN ARSENIC ACID ... SPLASHED ON WORKERS, INDICATING THAT THE SKIN IS POSSIBLE ROUTE OF ABSORPTION FOR ARSENIC.

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

雄性和雌性仓鼠通过口服或静脉注射的方式给予单剂量的砒酸(74)As (每只仓鼠33微居里;每只仓鼠0.01微克砒霜)。对于静脉注射的仓鼠，第一个组成部分(剂量的65%)的消除半衰期是0.40天;第二个组成部分(剂量的35%)的消除半衰期是4.5天。对于口服给药的仓鼠，第一个组成部分(剂量的98%)的消除半衰期是0.29天;第二个组成部分(剂量的2%)的消除半衰期是3.8天。口服给药仓鼠和静脉注射给药仓鼠之间剂量排泄百分比的差异可能是由于口服给药动物粪便中砒霜的排泄量增加(70%)，而静脉注射给药仓鼠的排泄量仅为6%。

MALE & FEMALE HAMSTERS WERE GIVEN EITHER A SINGLE ORAL OR IV DOSE OF (74)AS (33 MICROCURIES/HAMSTER; 0.01 UG ARSENIC/HAMSTER) AS ARSENIC ACID. FOR THE IV DOSED HAMSTERS, HALF-PERIOD OF ELIMINATION FOR THE 1ST COMPONENT (65% OF THE DOSE) WAS 0.40 DAYS; 2ND COMPONENT (35% OF THE DOSE) HAD HALF-PERIOD OF 4.5 DAYS. FOR THE ORALLY DOSED HAMSTERS, THE HALF-PERIOD OF ELIMINATION FOR 1ST COMPONENT (98% OF THE DOSE) WAS 0.29 DAYS; 2ND COMPONENT (2% OF THE DOSE) HAD A HALF-PERIOD OF 3.8 DAYS. DIFFERENCES IN THE PERCENT OF DOSE EXCRETED BETWEEN ORAL & IV DOSED HAMSTERS MAY BE DUE TO THE INCREASED FECAL EXCRETION OF ARSENIC (70%) IN THE ORALLY DOSED ANIMALS AS COMPARED TO THE IV DOSED HAMSTERS (6%).

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

给予无载体(74)As砒酸的裸鼠自动放射性显影显示，砷在肠粘膜以及肾脏中具有高亲和力。

Autoradiography of mice given carrier-free (74)As arsenic acid (iv) revealed a high affinity of As in the intestinal mucosa as well as in the kidneys.

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

(73)As 作为砒霜（H3AsO4）单独使用和与土壤混合后，通过尸体皮肤的经皮吸收已经得到了测量……标记的砷被应用到扩散细胞中的皮肤上，并测量其通过皮肤进入受体液的传输过程。24小时后，0.93%的剂量通过了皮肤，洗涤后有0.98%留在皮肤中。当(73)As与土壤混合时，吸收率较低：24小时内0.43%通过了皮肤，洗涤后有0.33%留在皮肤中。

Percutaneous absorption of (73)As as arsenic acid (H3AsO4) alone and mixed with soil has been measured in skin from cadavers ... . Labeled arsenic was applied to skin in diffusion cells and transit through the skin into receptor fluid measured. After 24 hr, 0.93% of the dose passed through the skin and 0.98% remained in the skin after washing. Absorption was lower with (73)As mixed with soil: 0.43% passed through the skin over 24 hr and 0.33% remained in the skin after washing.

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

皮肤对砷的吸收已经在猕猴身上进行了测量……24小时后，系统吸收了6.4%的As作为砷酸，以及4.5%与土壤混合的As。

Dermal absorption of arsenic has been measured in Rhesus monkeys ... . After 24 hr, 6.4% of (73)As as arsenic acid was absorbed systemically, as was 4.5% of (73)As mixed with soil.

来源:Hazardous Substances Data Bank (HSDB)

安全信息

• 危险等级：
  6.1
• 包装等级：
  II
• 危险类别：
  6.1(a)
• 危险品运输编号：
  1554
• 储存条件：
  请将密封保存放入段落中，并稍作润色：密封保存。

制备方法与用途

制备方法

将100克As2O3放入磨口烧瓶中，慢慢滴加100毫升相对密度为1.38的浓硝酸，同时加热。继续加热至不再产生氧化氮气体（可导入浓硫酸中作为硫酸亚硝酰酯收集），然后只分离上层澄清液并蒸干。残余物用少量水溶解后，通过玻璃过滤器进行过滤。将滤液加热浓缩至溶液温度达到130℃时停止，冷却后置于装有浓硫酸的干燥器中，在冷柜中析出结晶H3AsO4·0.5H2O。

合成制备方法

步骤与上述制备方法相同：将100克 放入磨口烧瓶中，慢慢滴加100毫升相对密度为1.38的浓硝酸，同时加热至不再产生氧化氮气体，分离上层澄清液并蒸干。残余物用少量水溶解后过滤，滤液加热浓缩至溶液温度达到130℃时停止，冷却后置于装有浓硫酸的干燥器中，在冷柜中析出结晶H3AsO4·0.5H2O。

用途简介

此方法用于制备砷酸盐（如砷酸钙、砷酸铅）杀虫剂。

用途

主要用于制备砷酸盐（如砷酸钙、砷酸铅）杀虫剂。

反应信息

• 作为反应物：
  描述：

  砷酸、原砷酸 在 盐酸 、 肼 作用下， 以 sodium hydroxide 为溶剂， 生成 三氯化砷
  参考文献：
  名称：

  Tarugi, N., Gazzetta Chimica Italiana, 1922, vol. 52, # II, p. 323 - 332

  摘要：

  DOI：
• 作为产物：
  描述：

  砷酸二氢钠 在 H₂SO₄ 作用下， 以 水 为溶剂， 生成 砷酸、原砷酸
  参考文献：
  名称：

  Gmelin Handbuch der Anorganischen Chemie, Gmelin Handbook: Na: SVol.4, 152, page 1698 - 1700

  摘要：

  DOI：
• 作为试剂：
  描述：

  1-羟基-2-甲氧基蒽醌 在 吡啶 、 盐酸 、 砷酸、原砷酸 、 溶剂黄146 、 tin(ll) chloride 作用下， 生成 7,15-dihydroxy-6,14-dimethoxy-dibenzo[a,j]perylene-8,16-dione
  参考文献：
  名称：

  XXII。-羟基蒽醌的还原产物。第十二部分

  摘要：

  DOI：

  10.1039/jr9310000144

文献信息

• [EN] IMPROVED PROCESS FOR MANUFACTURING ACROLEIN/ACRYLIC ACID<br/>[FR] PROCÉDÉ AMÉLIORÉ DE FABRICATION D'ACROLÉINE/ACIDE ACRYLIQUE
  申请人：ARKEMA FRANCE

  公开号：WO2012101526A1

  公开（公告）日：2012-08-02

  The present invention relates to the selective elimination of propanal in acrolein-rich streams to produce acrolein and/or acrylic acid and/or acrylonitrile and/or methylmercaptopropionaldehyde containing low amount of propanal and/or propionic acid and/or propionitrile. One subject of the present invention is a process for manufacturing acrolein comprising a step of selective elimination of propanal in an acrolein-rich stream in contact with a catalyst comprising at least molybdenum. Another subject of the present invention is a process for manufacturing acrylic acid from glycerol including a step of selective elimination of propanal in an acrolein- rich stream in contact with a catalyst comprising at least molybdenum.

  本发明涉及在丙烯醛富含流中选择性消除丙醛，以生产含有低量丙醛和/或丙酸和/或丙腈的丙烯醛和/或丙烯酸和/或丙烯腈和/或甲基巯基丙醛。本发明的一个主题是一种制造丙烯醛的方法，包括与至少钼组成的催化剂接触的丙烯醛富含流中选择性消除丙醛的步骤。本发明的另一个主题是从甘油制造丙烯酸的方法，包括与至少钼组成的催化剂接触的丙烯醛富含流中选择性消除丙醛的步骤。
• Synthesis and crystal structure of a novel galloarsenate containing the As3O10 5? triarsenate anion: Cs2Ga3As5O18
  作者：Kuan-Jiuh Lin、Kwang-Hwa Lii

  DOI：10.1039/cc9960001137

  日期：——

  The synthesis and crystal structure of Cs2Ga3As5O18 in which the Ga atoms are octahedrally and square-pyramidally coordinated are described: the three-dimensional structure is unique and contains the very rare triarsenate anion As3O105–.

  描述了Cs2Ga3As5O18的合成和晶体结构，其中Ga原子呈八面体和四角锥配位。其三维结构独特，并含有极为罕见的三砷酸盐阴离子As3O105⁻。
• Iron arsenate frameworks
  作者：Seth B. Wiggin、Robert W. Hughes、Daniel J. Price、Mark T. Weller

  DOI：10.1039/b702847d

  日期：——

  Six new iron arsenate framework structures, Fe2As2O7·2H2O, [Fe6As8O32H4]2−(1,4-butanediamininium2+)·2H2O, [Fe4As6O22H2]2−(piperazinium2+), [Fe5As5O24H4]2−(piperazinium2+)·2H2O, [Fe6As7O31H5]2−(dabco2+) and LiFeAsO4OH have been synthesised under hydrothermal conditions. Incorporation of the amine cation templates leads to more open framework geometries and, in contrast to iron phosphates which have topologies based on PO4 tetrahedra, the iron arsenate structures typically contain protonated As(O,OH)4 units. The magnetic properties of the iron arsenates studied show Curie–Weiss behaviours with maxima in the χ(T) vs.T plots in the range 10–50 K.

  合成了六种新的铁砷酸盐框架结构，分别为Fe2As2O7·2H2O, [Fe6As8O32H4]2−(1,4-丁二胺钠2+)·2H2O, [Fe4As6O22H2]2−(哌嗪钠2+), [Fe5As5O24H4]2−(哌嗪钠2+)·2H2O, [Fe6As7O31H5]2−(dabco2+)和LiFeAsO4OH，这些结构是在水热条件下合成的。胺阳离子模板的加入导致框架几何形状更加开放，与基于PO4四面体的铁磷酸盐相比，铁砷酸盐结构通常包含质子化的As(O,OH)4单元。研究显示，所研究的铁砷酸盐的磁性质表现出居里-魏斯行为，在10–50 K范围内的χ(T)与T图中出现最大值。
• Synthesis and Characterization of Fluorinated Metal Arsenates with a Layer Structure:  (C₄H₁₂N₂)_1.5[M₃F₅(HAsO₄)₂(AsO₄)] (M = Fe, Ga)
  作者：Shi-Hao Luo、Yau-Chen Jiang、Sue-Lein Wang、Hsien-Ming Kao、Kwang-Hwa Lii

  DOI：10.1021/ic010150q

  日期：2001.10.1

  Two fluorinated metal arsenates, (C(4)H(12)N(2))(1.5)[M(3)F(5)(HAsO(4))(2)(AsO(4))] (M = Fe, Ga), have been synthesized under hydrothermal conditions and characterized by single-crystal X-ray diffraction, magnetic susceptibility, Mössbauer spectroscopy, and (71)Ga NMR spectroscopy. The two compounds are isostructural and crystallize in the monoclinic space group P2(1)/c (No. 14) with a = 8.394(1) A

  两个氟化金属砷酸盐（（C（4）H（12）N（2））（1.5）[M（3）F（5）（HAsO（4））（2）（AsO（4））]（M = Fe，Ga）已在水热条件下合成，并通过单晶X射线衍射，磁化率，Mössbauer光谱和（71）Ga NMR光谱进行了表征。这两种化合物是同构的，在单斜空间群P2（1）/ c（第14号）中结晶，a = 8.394（1）A，b = 21.992（3）A，c = 10.847（1）A，beta = Fe化合物为96.188（2）度，Z = 4，a = 8.398（1）A，b = 21.730（3）A，c = 10.679（1）A，β= 95.318（2）度，Z对于Ga化合物= 4。该结构由角共享MX（6）（X = O，F）八面体和边缘共享MO（3）F（3）八面体的二聚体组成的无限链组成，它们通过砷酸四面体与薄片之间的双质子化的哌嗪鎓阳离子连接成二维薄片。磁化率和Mös
• Investigations in the Systems Ag-Hg-X-O (X = As^V, Se^IV, Se^VI): Hydrothermal Single Crystal Growth of Ag₃AsO₄, AgHg^I ₂AsO₄, AgHg^IIAsO₄, Ag₂SeO₄ and the Crystal Structure of Ag₂Hg^II(SeO₃)₂
  作者：Matthias Weil

  DOI：10.1515/znb-2003-1110

  日期：2003.11.1

  Single crystals of the already known phases Ag₃AsO₄, AgHg^I ₂AsO₄, AgHg^IIAsO₄, Ag₂SeO₄ and of the hitherto unknown compound Ag₂Hg^II(SeO₃)₂ were obtained under hydrothermal conditions (250 °C, 5d) from starting mixtures of the metal nitrates and the respective acids. Both Ag₃AsO₄ and AgHg^I ₂AsO₄ are isotypic with the corresponding phosphates, Ag₃PO₄ and AgHg^I ₂PO₄, whereas AgHg^IIAsO₄ and Ag₂SeO₄ crystallize in the thenardite (Na₂SO₄ (V)) structure. All crystal structures were refined by means of single crystal X-ray data. The crystal structure of Ag2Hg^II(SeO₃)₂ [Pbca, Z = 8, a = 6.8206(11), b = 11.237(3), c = 16.876(2) Å , 1677 structure factors, 101 parameters, R[F² > 2σ (F²)] = 0.0193, wR(F² all) =0.0394] consists of considerably distorted [AgO₆] and [HgO₆] octahedra, and trigonal Se^IVO₃ pyramids as the main building units. The [MO₆] octahedra build a complex framework by sharing common edges and corners, and the Se^IVO₃ pyramids are located in the vacancies of this arrangement. The average Hg-O distance of 2.399 Å is significantly shorter than the average Ag-O distance of 2.551Å . The geometries of the two crysta̱llographically independent Se^IVO₃ pyramids are very similar and the average distance and angle (d(Se-O) = 1.709 Å , ∠(O-S-O) = 100.1°) lie in the characteristic range for a selenite(IV) group. A short comparative structural discussion between the various compounds obtained during the hydrothermal experiments is given.

  在250°C、5天的水热条件下，从金属硝酸盐和相应酸的起始混合物中得到了已知相Ag₃AsO₄、AgHg^I₂AsO₄、AgHg^IIAsO₄、Ag₂SeO₄以及迄今为止未知的化合物Ag₂Hg^II(SeO₃)₂的单晶。Ag₃AsO₄和AgHg^I₂AsO₄与相应的磷酸盐Ag₃PO₄和AgHg^I₂PO₄同晶，而AgHg^IIAsO₄和Ag₂SeO₄结晶于thenardite（Na₂SO₄（V））结构中。所有晶体结构都通过单晶X射线数据进行了精确修正。Ag2Hg^II(SeO₃)₂的晶体结构[Pbca，Z = 8，a = 6.8206(11)，b = 11.237(3)，c = 16.876(2) Å，1677个结构因子，101个参数，R[F² > 2σ(F²)] = 0.0193，wR(F² all) = 0.0394]由明显扭曲的[AgO₆]和[HgO₆]八面体以及三角形的Se^IVO₃金字塔作为主要构建单元组成。[MO₆]八面体通过共享公共边和角构建复杂的框架，Se^IVO₃金字塔位于这种排列的空位中。平均Hg-O距离为2.399 Å，明显短于平均Ag-O距离2.551 Å。两个晶体学上独立的Se^IVO₃金字塔的几何形状非常相似，平均距离和角度（d(Se-O) = 1.709 Å，∠(O-S-O) = 100.1°）处于硒酸盐（IV）群的特征范围内。对水热实验中得到的各种化合物进行了简短的结构比较讨论。